A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton
Mark J
MJ
Hicks
Rodney J
RJ
Westerman
David A
DA
Prince
Miles H
MH
Wolf
Max
M
Seymour
John F
JF
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18 / Q000494:pharmacology*; D006801:Humans; D007457:Iodine Radioisotopes / Q000494:pharmacology*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016499:Radioimmunotherapy / Q000379:methods*; D012074:Remission Induction; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D019788:Fluorodeoxyglucose F18; D000069283:Rituximab